Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Wed, Oct 22, 2025
[Archive]
Volume 16, Issue 4 (Autumn 2025)
Caspian J Intern Med 2025, 16(4): 588-598 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soltanzadi A, Mirmosayyeb O, Momeni Moghaddam A, Vaheb S, Ghajarzadeh M. Intra-detrusor injection of Onabotulinumtoxin for lower urinary tract symptoms (LUTS) symptoms in patients with multiple sclerosis (MS): a systematic review and meta-analysis.. Caspian J Intern Med 2025; 16 (4) :588-598
URL: http://caspjim.com/article-1-4054-en.html
URL: http://caspjim.com/article-1-4054-en.html
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran , m.ghajarzadeh@gmail.com
Abstract: (347 Views)
Background: Lower urinary tract symptoms (LUTS) are common complications in patients with multiple sclerosis (MS). Different studies evaluated the effects of Onabotulinumtoxin on urinary findings in patients with MS. We designed this systematic review and meta-analysis to estimate pooled efficacy of intra-detrusor injections of botox for urinary symptoms in patients with MS.
Methods: A comprehensive systematic search was conducted on five databases of PubMed, Scopus, EMBASE, Web of Science, and Google scholar on February 2022. . We extracted data regarding the total number of participants, first author, publication year, the country of origin, mean age, F/M ratio, duration of the disease, duration of the treatment, mean Expanded Disability Status Scale (EDSS), maximum cystometric capacity (MCC), and maximum detrusor pressure (MDP).
Results: Preliminary search of databases retrieved 1618 articles, after deduplication, 934 studies remained. Five studies were included for meta-analysis. The most frequent country of origin was the USA, and the mean EDSS ranged between 2.9 and 5.1. Urinary tract infection (UTI) and urinary retention were the most prevalent complications. The SMD of MDP (MDP week 12-MDP baseline) was -1.32(95%CI:-1.77, -0.37) (I2=52.9%, P=0.1). The SMD of MCC (MCC week 12-MCC baseline) was 1.65 (95%CI: 0.44, 2.86) (I2=92.4%, p<0.001). The SMD of MDP (MDP week 4-MDP baseline) was -3.6 (95%CI:-7.3, 0.16) (I2=98.3%, p<0.001). The SMD of MCC (MCC week 4-MCC baseline) was 5.05 (95%CI: 0.14, 9.96) (I2=98.8%, p<0.001).
Conclusions: This systematic review and meta-analysis demonstrated that injection of intra-detrusor Onabotulinumtoxin had a positive effect on improving urodynamic findings in patients with MS.
Methods: A comprehensive systematic search was conducted on five databases of PubMed, Scopus, EMBASE, Web of Science, and Google scholar on February 2022. . We extracted data regarding the total number of participants, first author, publication year, the country of origin, mean age, F/M ratio, duration of the disease, duration of the treatment, mean Expanded Disability Status Scale (EDSS), maximum cystometric capacity (MCC), and maximum detrusor pressure (MDP).
Results: Preliminary search of databases retrieved 1618 articles, after deduplication, 934 studies remained. Five studies were included for meta-analysis. The most frequent country of origin was the USA, and the mean EDSS ranged between 2.9 and 5.1. Urinary tract infection (UTI) and urinary retention were the most prevalent complications. The SMD of MDP (MDP week 12-MDP baseline) was -1.32(95%CI:-1.77, -0.37) (I2=52.9%, P=0.1). The SMD of MCC (MCC week 12-MCC baseline) was 1.65 (95%CI: 0.44, 2.86) (I2=92.4%, p<0.001). The SMD of MDP (MDP week 4-MDP baseline) was -3.6 (95%CI:-7.3, 0.16) (I2=98.3%, p<0.001). The SMD of MCC (MCC week 4-MCC baseline) was 5.05 (95%CI: 0.14, 9.96) (I2=98.8%, p<0.001).
Conclusions: This systematic review and meta-analysis demonstrated that injection of intra-detrusor Onabotulinumtoxin had a positive effect on improving urodynamic findings in patients with MS.
Policy Brief: Review Article |
Subject:
Neurology
Received: 2023/08/21 | Accepted: 2024/05/21 | Published: 2025/09/9
Received: 2023/08/21 | Accepted: 2024/05/21 | Published: 2025/09/9
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
